NFE2L2 and breast carcinoma: Univariate survival analysis of all 1942 breast cancer patients revealed that patients with high NFE2L2 mRNA expression levels had a better DSS (P = 0.005) and OS (P = 0.003) in comparison to those with low NFE2L2 mRNA expression levels (Table 2; Fig. 1a, b).